BOARD OF DIRECTORS
Before joining in Adams Street in 1994, Mr. Gould was with Trinity Ventures, Ltd. and spent five years as a management consultant, including experience with the Boston Consulting Group, an international strategy consulting firm. He also has experience as a founder and executive in two successful entrepreneurial companies.
Terry is a graduate of Dartmouth College, BA and Stanford University Graduate School of Business, MBA.
Prior to co-founding Genesys Capital, Mr. Lamb was an Investment Manager with MDS Capital Corp. He is a frequently invited speaker at biotechnology industry conferences and was a judge for the BioNorth Top 10 Canadian Life Sciences Companies contest from 2000 to 2008.
Mr. Lamb graduated from McMaster University, Faculty of Health Sciences, with an M.S. in Molecular Neurobiology and also holds an MBA from Queen’s University.
Prior to TPG, Dr. Nadav was Business Development Director at Eisai in New Jersey, where he evaluated and negotiated licensing and acquisition deals. Previously, Dr. Nadav worked for JJDC, the venture capital subsidiary of Johnson & Johnson. Earlier, he worked for Neurim Pharmaceuticals in a product development role.
Dr. Nadav holds a Ph.D. in Biochemistry, an M.Sc. magna cum laude, a B.Sc. magna cum laude, and an MBA from Tel Aviv University.
Dr. Nadav is currently a board member at Carisma Therapeutics, Fusion Pharmaceuticals, Nutrinia, Trevi Therapeutics, and Tevel Aerobotics Technologies. He is also a member at the Investment Committee at Lagunita Biosciences, a healthcare investment company and incubator. Representing TPG, Dr. Nadav was the lead investor and Chairman of the Board of Ultragenyx Pharmaceutical (Nasdaq: RARE) and Trevi Therapeutics. His other past investments and board roles include Collegium Pharmaceutical (Nasdaq: COLL), JCR Pharmaceuticals (a Japanese biopharma company, TSE: 4552), MacroGenics (Nasdaq: MGNX), ShangPharma (a China based CRO), and Eden Springs / Mey Eden (a leading European provider of workplace drinks solutions).
Heather currently serves on the board of directors of Oxford Biomedica (LSE:OXB); Alder BioPharmaceuticals (NASDAQ:ALDR); Otonomy, Inc. (NASDAQ:OTIC); Entasis Therapeutics (NASDAQ:ETTX), Unchained Labs, Azura Opthalmics, Fusion Pharmaceuticals and Karuna Therapeutics. She is an observer on the board of Avalyn Pharmaceuticals. She has previously served on multiple boards including Albireo (NASDAQ:ALBO), Aptalis Pharma (acquired by Forest Labs in 2014), and Elevation Pharmaceuticals (acquired by Sunovion in 2012). She was responsible for TPG Biotech’s investment in Par Pharmaceuticals (acquired by Endo Pharmaceuticals in 2015).
Heather has an undergraduate degree in biochemistry from the University of London and a medical degree from the University of Oxford. She completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University and trained in Internal Medicine at the Massachusetts General Hospital, Harvard and sub-specialized in Gastroenterology and Hepatology at UCSF. During her academic medical career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award. Dr. Preston also serves on the Board of Trustees for the Harvard Discovery Council, the Fine Arts Museums of San Francisco, Saint Luke’s School and the Harlech Scholarship Foundation.
Prior to Fusion, Dr. Valliant founded the Centre for Probe Development and Commercialization (CPDC), a radiopharmaceutical research and development centre of excellence established in 2008 through funding from the Federal and Provincial governments, industry and academic partners. The CPDC is focused on discovering, developing and distributing the next generation of molecular imaging probes. The CPDC also plays an important role in Canada’s health care system, manufacturing and delivering a reliable, daily supply of imaging probes to hospitals and clinics nationally and internationally.
Dr. Valliant is also a Professor in the Department of Chemistry and Chemical Biology at McMaster University. His current research focuses on developing new radiolabeling methods and compound discovery strategies to create clinically relevant molecular imaging probes and therapeutic radiopharmaceuticals.
In 2009, Dr. Valliant was selected as one of Canada’s Top 40, Under 40, a distinction that recognizes his work at CPDC and McMaster University to advance molecular imaging probe technologies, improve patient care and spur economic growth through commercialization of Canadian technologies. In 2015, he received the Brockhouse Canada Prize for Interdisciplinary Research in Science and Engineering from NSERC, recognizing his contribution to a team of researchers from physics, chemistry and nuclear medicine, who developed breakthrough technology that uses hospital-based cyclotrons to produce critical medical isotopes.
Dr. Valliant completed his PhD at McMaster University, and followed with a post-doctoral fellowship under the joint supervision of professors Alun G. Jones (Harvard) and Alan Davison (MIT).
Dr. Xavier previously worked in business development at BioRexis Pharmaceutical Corporation which was acquired by Pfizer in 2007. While at BioRexis, he assisted the company in raising a million second round of financing. Dr. Xavier has worked in business development at Structural GenomiX, Inc., acquired by Eli Lilly in 2008, and was a project leader at Message Pharmaceuticals, Inc.
Dr. Xavier received a PhD from the University of Houston in Chemical Engineering, and a MBA from the Wharton School of the University of Pennsylvania, where he graduated with honors. He received a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. Dr. Xavier was a postdoctoral research Fellow in the Department of Chemistry at Johns Hopkins University.